HSV-1 viral oncolysis and molecular imaging with PET

Current Cancer Drug Targets

Volumn 7, Issue 2, 2007, Pages 175-180

  Kuruppu, Darshini ^a   Dorfman, Jon D ^a   Tanabe, Kenneth K ^a  

^a MASSACHUSETTS GENERAL HOSPITAL   (United States)

Author keywords

G207; hrR3; HSV 1; HSV TK; NV1020; Positron emission tomography; Replication conditional virus; rRp45; Viral oncolysis

Indexed keywords

3 (2 FLUOROETHYL)SPIPERONE; CYTOSINE DEAMINASE; FLUCYTOSINE; G 207; HSV 1716; HSV1YCD; MYB 34 5; NV 1020; ONCOLYTIC HERPES VIRUS; RRP 450; UNCLASSIFIED DRUG;

ANTINEOPLASTIC ACTIVITY; CANCER CELL; CANCER CELL DESTRUCTION; CANCER THERAPY; COLORECTAL CARCINOMA; DRUG POTENTIATION; DRUG SENSITIVITY; GENETIC ENGINEERING; HERPES SIMPLEX VIRUS 1; HUMAN; IMAGING SYSTEM; NONHUMAN; POSITRON EMISSION TOMOGRAPHY; REVIEW; SITE DIRECTED MUTAGENESIS; TRANSGENE; TUMOR BIOPSY; VIRUS REPLICATION;

ANIMALS; HERPESVIRUS 1, HUMAN; HUMANS; NEOPLASMS; ONCOLYTIC VIROTHERAPY; POSITRON-EMISSION TOMOGRAPHY; TREATMENT OUTCOME; VIRUS REPLICATION;

EID: 33847398321     PISSN: 15680096     EISSN: None     Source Type: Journal    
DOI: 10.2174/156800907780058871     Document Type: Review

References (37)

1. Dock, G. Rabies virus vaccination in a patient with cervical carcinoma. Am. J. Med. Sci. 1904, 127, 563.
2. Newman, W.; Southam, C. M. Virus treatment in advanced cancer. Cancer 1954, 7, 106-118.
3. Cassel, W. A.; Garrett, R. E. Newcastle disease virus as an antineoplastic agent. Cancer 1965, 18, 863-868.
4. Mullen, J.; Tanabe, K. Viral oncolysis. Oncologist 2002, 7, 106-119.
5. Martuza, R. L. Conditionally replicating herpes vectors for cancer therapy. J. Clin. Invest. 2000, 105, 841-846.
6. Roizman, B.; Sears, A. E. Herpes simplex viruses and their replication. In Fields Virolog; 3rd Ed.; Fields, B. N.; Knipe, D. M.; Howley, P. M.; Eds.; Lippincott: Philadelphia, 1996, pp. 2231-2295.
7. Goldstein, D. J.; Weller, S. K. Herpes simplex virus type 1-induced ribonucleotide reductase activity is dispensable for virus growth and DNA synthesis: isolation and characterization of an ICP6 lacZ insertion mutant. J. Virol. 1988, 62, 196-205.
8. Mullen, J. T.; Kasuya, H.; Yoon, S. S.; Carroll, N. M.; Pawlik, T. M.; Chandrasekhar, S.; Nakamura, H.; Donahue, J. M.; Tanabe, K. K. Regulation of herpes simplex virus 1 replication using tumor-associated promoters. Ann. Surg. 2002, 236, 502-512; discussion 512-503.
9. Martuza, R. L.; Malick, A.; Markert, J. M.; Ruffner, K. L.; Coen, D. M. Experimental therapy of human glioma by means of a genetically engineered virus mutant. Science 1991, 252, 854-856.
10. Carroll, N. M.; Chiocca, E. A.; Takahashi, K.; Tanabe, K. K. Enhancement of gene therapy specificity for diffuse colon carcinoma liver metastases with recombinant herpes simplex virus. Ann. Surg. 1996, 224, 323-329; discussion 329-330.
11. Yoon, S. S.; Nakamura, H.; Carroll, N. M.; Bode, B. P.; Chiocca, E. A.; Tanabe, K. K. An oncolytic herpes simplex virus type 1 selectively destroys diffuse liver metastases from colon carcinoma. FASEB J. 2000, 14, 301-311.
12. Chase, M.; Chung, R.; Chiocca, E. A. An oncolytic viral mutant that delivers the CYP2B1 transgene and augments cyclophosphamide chemotherapy. Nat. Biotech. 1998, 16, 444-448.
13. Pawlik, T. M.; Nakamura, H.; Mullen, J. T.; Kasuya, H.; Yoon, S. S.; Chandrasekhar, S.; Chiocca, E. A.; Tanabe, K. K. Prodrug bioactivation and oncolysis of diffuse liver metastases by a herpes simplex virus 1 mutant that expresses the CYP2B1 transgene. Cancer 2002, 95, 1171-1181.
14. Detta, A.; Harland, J.; Hanif, I.; Brown, S. M.; Cruickshank, G. Proliferative activity and in vitro replication of HSV1716 in human metastatic brain tumours. J. Gene Med. 2003, 5, 681-689.
15. Harrow, S.; Papanastassiou, V.; Harland, J.; Mabbs, R.; Petty, R.; Fraser, M.; Hadley, D.; Patterson, J.; Brown, S. M.; Rampling, R. HSV1716 injection into the brain adjacent to tumour following surgical resection of high-grade glioma: safety data and long-term survival. Gene Ther. 2004, 11, 1648-1658.
16. Chung, R. Y.; Saeki, Y.; Chiocca, E. A. B-myb promoter retargeting of herpes simplex virus gamma 34.5 gene-mediate virulence toward tumor and cycling cells. J. Virol. 1999, 73, 7556-7564.
17. 134.5 expression and oncolysis of diffuse liver metastases by Myb34.5. J. Clin. Invest. 2002, 109, 871-882.
18. Yazaki, T.; Manz, H. J.; Rabkin, S. D.; Martuza, R. L. Treatment of human malignant meningiomas by G207, a replication-competent multimutated herpes simplex virus 1. Cancer Res. 1995, 55, 4752-4756.
19. Todo, T.; Rabkin, S. D.; Martuza, R. L. Evaluation of ganciclovir-mediated enhancement of the antitumoral effect in oncolytic, multimutated herpes simplex virus type 1 (G207) therapy of brain tumors. Cancer Gene Ther. 2000, 7, 939-946.
20. Hunter, W. D.; Martuza, R. L.; Feigenbaum, F.; Todo, T.; Mineta, T.; Yazaki, T.; Toda, M.; Newsome, J. T.; Platenberg, R. C.; Manz, H. J.; Rabkin, S. D. Attenuated, replication-competent herpes simplex virus type 1 mutant G207: safety evaluation of intracerebral injection in nonhuman primates. J. Virol. 1999, 73, 6319-6326.
21. Markert, J. M.; Medlock, M. D.; Rabkin, S. D.; Gillespie, G. Y.; Todo, T.; Hunter, W. D.; Palmer, C. A.; Feigenbaum, F.; Tornatore, C.; Tufaro, F.; Martuza, R. L. Conditionally replicating herpes simplex virus mutant, G207 for the treatment of malignant glioma: results of a phase I trial [see comments]. Gene Ther. 2000, 7, 867-874.
22. Meignier, B.; Longnecker, R.; Roizman, B. In vivo behavior of genetically engineered herpes simplex viruses R7017 and R7020: construction and evaluation in rodents. J. Infect. Dis. 1988, 158, 602-614.
23. Meignier, B.; Martin, B.; Whitley, R. J.; Roizman, B. In vivo behavior of genetically engineered herpes simplex viruses R7017 and R7020. II. Studies in immunocompetent and immunosuppressed owl monkeys (aotus trivirgatus). J. Infect. Dis. 1990, 162, 313-321.
24. Bennett, J. J.; Delman, K. A.; Burt, B. M.; Mariotti, A.; Malhotra, S.; Zager, J.; Petrowsky, H.; Mastorides, S.; Federoff, H.; Fong, Y. Comparison of safety, delivery, and efficacy of two oncolytic herpes viruses (G207 and NV1020) for peritoneal cancer. Cancer Gene Ther. 2002, 9, 935-945.
25. Nakamura, H.; Mullen, J. T.; Chandrasekhar, S.; Pawlik, T. M.; Yoon, S. S.; Tanabe, K. K. Multimodality therapy with a replication-conditional herpes simplex virus 1 mutant that expresses yeast cytosine deaminase for intratumoral conversion of 5-fluorocytosine to 5-fluorouracil. Cancer Res. 2001, 61, 5447-5452.
26. Weissleder, R.; Ntziachristos, V. Shedding light onto live molecular targets. Nat. Med. 2003, 9, 123-128.
27. Schellingerhout, D.; Rainov, N. G.; Breakefield, X. O.; Weissleder, R. Quantitation of HSV mass distribution in a rodent brain tumor model. Gene Ther. 2000, 7, 1648-1655.
28. Penuelas, I.; Boan, J.; Marti-Climent, J. M.; Sangro, B.; Mazzolini, G.; Prieto, J.; Richter, J. A. Positron emission tomography and gene therapy: basic concepts and experimental approaches for in vivo gene expression imaging. Mol. Imaging Biol. 2004, 6, 225-238.
29. MacLaren, D. C.; Gambhir, S. S.; Satyamurthy, N.; Barrio, J. R.; Sharfstein, S.; Toyokuni, T.; Wu, L.; Berk, A. J.; Cherry, S. R.; Phelps, M. E.; Herschman, H. R. Repetitive, non-invasive imaging of the dopamine D2 receptor as a reporter gene in living animals. Gene Ther. 1999, 6, 785-791.
30. Liang, Q.; Satyamurthy, N.; Barrio, J. R.; Toyokuni, T.; Phelps, M. P.; Gambhir, S. S.; Herschman, H. R. Noninvasive, quantitative imaging in living animals of a mutant dopamine D2 receptor reporter gene in which ligand binding is uncoupled from signal transduction. Gene Ther. 2001, 8, 1490-1498.
31. Gambhir, S. S.; Bauer, E.; Black, M. E.; Liang, Q.; Kokoris, M. S.; Barrio, J. R.; Iyer, M.; Namavari, M.; Phelps, M. E.; Herschman, H. R. A mutant herpes simplex virus type 1 thymidine kinase reporter gene shows improved sensitivity for imaging reporter gene expression with positron emission tomography. Proc. Natl. Acad. Sci. USA 2000, 97, 2785-2790.
32. Tjuvajev, J. G.; Doubrovin, M.; Akhurst, T.; Cai, S.; Balatoni, J.; Alauddin, M. M.; Finn, R.; Bornmann, W.; Thaler, H.; Conti, P. S.; Blasberg, R. G. Comparison of radiolabeled nucleoside probes (FIAU, FHBG, and FHPG) for PET imaging of HSV1-tk gene expression. J. Nucl. Med. 2002, 43, 1072-1083.
33. Alauddin, M. M.; Shahinian, A.; Gordon, E. M.; Conti, P. S. Direct comparison of radiolabeled probes FMAU, FHBG, and FHPG as PET imaging agents for HSV1-tk expression in a human breast cancer model. Mol. Imaging 2004, 3, 76-84.
34. Gambhir, S. S. Molecular imaging of cancer with positron emission tomography. Nat. Rev. Cancer 2002, 2, 683-693.
35. Green, L. A.; Nguyen, K.; Berenji, B.; Iyer, M.; Bauer, E.; Barrio, J. R.; Namavari, M.; Satyamurthy, N.; Gambhir, S. S. A tracer kinetic model for 18F-FHBG for quantitating herpes simplex virus type 1 thymidine kinase reporter gene expression in living animals using PET. J. Nucl. Med. 2004, 45, 1560-1570.
36. Bennett, J. J.; Tjuvajev, J.; Johnson, P.; Doubrovin, M.; Akhurst, T.; Malholtra, S.; Hackman, T.; Balatoni, J.; Finn, R.; Larson, S. M.; Federoff, H.; Blasberg, R.; Fong, Y. Positron emission tomography imaging for herpes virus infection: Implications for oncolytic viral treatments of cancer. Nat. Med. 2001, 7, 859-863.
37. Jacobs, A.; Tjuvajev, J. G.; Dubrovin, M.; Akhurst, T.; Balatoni, J.; Beattie, B.; Joshi, R.; Finn, R.; Larson, S. M.; Herrlinger, U.; Pechan, P. A.; Chiocca, E. A.; Breakefield, X. O.; Blasberg, R. G. Positron emission tomography-based imaging of transgene expression mediated by replication-conditional, oncolytic herpes simplex virus type 1 mutant vectors in vivo. Cancer Res. 2001, 61, 2983-2995.